Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bo
Non vérifié

Boehringer Ingelheim Limited

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiqueManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

32 communiqués de presse

Voir tous les communiqués de presse
28/11/2025
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim announces appointment to Board of Managing Directors
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
04/11/2025
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
29/10/2025
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
22/10/2025
Industrie pharmaceutique
Médecine Santé Bien-être
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
17/10/2025
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
15/10/2025
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
09/10/2025
Industrie pharmaceutique
Médecine Santé Bien-être
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
28/09/2025
Industrie pharmaceutique
Médecine Santé Bien-être
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
01/09/2025
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
18/08/2025
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0